Regeneron Pharmaceuticals, Inc.REGNNASDAQ
LOADING
|||
EBITDA Over Time
Trending higher, above historical average, strong compound growth.
Left:
||||
Earnings before interest, taxes, depreciation, and amortization
Latest
$5.32B
↑ 35% above average
Average (9y)
$3.94B
Historical baseline
Range
High:$9.67B
Low:$1.31B
CAGR
+16.8%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $5.32B | +13.3% |
| 2023 | $4.69B | -10.8% |
| 2022 | $5.26B | -45.6% |
| 2021 | $9.67B | +135.7% |
| 2020 | $4.10B | +53.7% |
| 2019 | $2.67B | -2.2% |
| 2018 | $2.73B | +21.4% |
| 2017 | $2.25B | +56.0% |
| 2016 | $1.44B | +9.7% |
| 2015 | $1.31B | - |